Recruiting
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis - IM011-1105
Oppdatert:
14 desember, 2023
|
ClinicalTrials.gov
Kjønn
Aldersgruppe
Sted(er)
Recruiting
Inclusion Criteria: - Have been diagnosed with plaque psoriasis by a dermatologist - Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) - Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: - Currently participating in an interventional clinical trial (does not include observational registry or study)
Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon
MLTNO2000046